GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pridopidine

Company
Prilenia
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pridopidine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07322003

    Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

    Not yet reported Prilenia 500 participants Est. completion 2029-03 55 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07609108

    Pridopidine Phase 3 Study in Huntington's Disease

    Not yet reported Prilenia 400 participants Est. completion 2030-06 66 sites Stand-alone
    Other conditions: Huntington Disease
    View official trial listing →
  • Completed NCT NCT00665223

    A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 437 participants Est. completion 2010-06-14 31 sites
    Other conditions: Huntington's Disease
    View official trial listing →
  • Completed NCT NCT00724048

    A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

    Not yet reported Teva Branded Pharmaceutical Products R&D, Inc. 227 participants Est. completion 2010-07-26 28 sites
    Other conditions: Huntington Disease
    View official trial listing →
  • Completed NCT NCT01306929

    Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

    Not yet reported Prilenia 134 participants Est. completion 2018-01-05 Stand-alone
    Other conditions: Huntington Disease
    View official trial listing →
  • Completed NCT NCT02006472

    A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

    Not yet reported Prilenia 408 participants Est. completion 2016-07-07 58 sites Stand-alone
    Other conditions: Huntington's Disease
    View official trial listing →
  • Terminated NCT NCT02494778

    A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

    Not yet reported Prilenia 248 participants Est. completion 2018-01-12 46 sites Stand-alone
    Other conditions: Huntington's Disease
    View official trial listing →
  • Completed NCT NCT03019289

    A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

    Not yet reported Prilenia 23 participants Est. completion 2018-02-09 1 site Stand-alone
    Other conditions: Health Volunteers, Huntington Disease
    View official trial listing →
  • Terminated NCT NCT03922711

    A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

    Not yet reported Prilenia 23 participants Est. completion 2020-07-22 33 sites Stand-alone
    Other conditions: Parkinson Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04297683

    HEALEY ALS Platform Trial - Master Protocol

    Not yet reported, Not yet reported Merit E. Cudkowicz, MD 1500 participants Est. completion 2028-08 81 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT04556656

    PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

    Not yet reported Prilenia 499 participants Est. completion 2024-03-21 58 sites Stand-alone
    Other conditions: Huntington Disease
    View official trial listing →
  • Completed NCT NCT04615923

    HEALEY ALS Platform Trial - Regimen D Pridopidine

    Not yet reported, Not yet reported Merit E. Cudkowicz, MD 163 participants Est. completion 2022-07-14 1 site Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • No Longer Available NCT NCT06069934

    A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

    Prilenia 32 sites
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.